Veeprho Pharmaceuticals
Veeprho Pharmaceuticals, a prominent player in the pharmaceutical industry, is headquartered in Great Britain and operates extensively across Europe and Asia. Founded in 2015, the company has rapidly established itself as a leader in the development of innovative therapies, particularly in the fields of oncology and neurology. Veeprho's core offerings include a range of advanced biopharmaceuticals that leverage cutting-edge research and technology, setting them apart in a competitive market. The company is recognised for its commitment to quality and efficacy, achieving significant milestones such as successful clinical trials and strategic partnerships. With a strong market position, Veeprho Pharmaceuticals continues to make strides in improving patient outcomes, solidifying its reputation as a trusted name in healthcare innovation.
DitchCarbon Score
How does Veeprho Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Veeprho Pharmaceuticals's score of 3 is higher than 66% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Veeprho Pharmaceuticals's reported carbon emissions
Veeprho Pharmaceuticals, headquartered in Great Britain, currently does not have publicly available carbon emissions data for the most recent year. As a result, specific figures regarding their emissions in kg CO2e, including Scope 1, 2, or 3 emissions, are not provided. In the absence of detailed emissions data, it is important to note that Veeprho Pharmaceuticals has not outlined any specific reduction targets or initiatives related to carbon emissions. There are no commitments to the Science Based Targets initiative (SBTi) or other climate pledges mentioned, indicating a potential area for development in their sustainability strategy. As the pharmaceutical industry increasingly focuses on reducing its carbon footprint, Veeprho Pharmaceuticals may benefit from establishing clear climate commitments and measurable targets to align with industry standards and expectations.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Veeprho Pharmaceuticals is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
